目的 观察苏黄止咳胶囊和布地格福吸入气雾剂联合治疗老年缓解期慢性阻塞性肺疾病（COPD）患者的临床疗效。方法 选取2024年3月—2025年2月首都医科大学附属北京积水潭医院老年内科、呼吸内科、全科医疗科、干部科收治的96例老年缓解期COPD患者，依据组间匹配原则将患者分为对照组和治疗组，每组各48例。对照组给予布地格福吸入气雾剂，2揿/次，2次/d。治疗组在对照组治疗基础上口服苏黄止咳胶囊，3粒/次，3次/d。两组均连续治疗6周。观察两组治疗效果，比较两组血清炎症因子[白细胞介素-17（IL-17）、白细胞介素-8（IL-8）、肿瘤坏死因子-α（TNF-α）、C反应蛋白（CRP）]、肺功能相关指标[呼吸峰流速（PEF）、最大呼气压（MEP）、第1秒用力呼气容积（FEV1）、FEV1/FVC]、氧化应激反应指标[丙二醛（MDA）、超氧化物歧化酶（SOD）、还原型谷胱甘肽（GSH）]、COPD评估测试（CAT）问卷评分。结果 治疗后，治疗组总有效率是97.92%，显著高于对照组的79.17（P＜0.05）。治疗后，两组IL-17、IL-8、TNF-α、CRP均较同组治疗前显著降低（P＜0.05）；治疗后治疗组IL-17、IL-8、TNF-α、CRP均低于对照组（P＜0.05）。治疗后，两组PEF、MEP、FEV1、FEV1/FVC均升高（P＜0.05）；治疗后，治疗组PEF、MEP、FEV1、FEV1/FVC高于对照组（P＜0.05）。治疗后，两组MDA下降，而SOD、GSH升高（P＜0.05）；治疗后，治疗组MDA低于对照组，SOD、GSH高于对照组（P＜0.05）。治疗后，两组CAT均较同组治疗前显著下降（P＜0.05）；治疗后，治疗组CAT低于对照组（P＜0.05）。结论 苏黄止咳胶囊联合布地格福吸入气雾剂可提高老年缓解期COPD患者临床疗效，纠正炎症状态，改善氧化应激反应，增强肺功能，对提高患者生活质量指数也有益。

Objective To investigate the therapeutic effect of Suhuang Zhike Capsules combined with budigafol in treatment of remission period of chronic obstructive pulmonary disease in the elderly. Methods A total of 96 elderly patients with COPD in remission who were admitted to the Department of Geriatrics, Department of Respiratory Medicine, Department of General Practice and Department of Cadre Medicine of Beijing Jishuitan Hospital, Capital Medical University from March 2024 to February 2025 were selected. According to the principle of matching between groups, the patients were divided into control group and treatment group, with 48 cases in each group. Patients in control group were given Budesonide, Glycopyrronium Bromide and Formoterol Fumarate Inhalation Aerosol, 2 puffs each time, twice daily. Patients in treatment group took orally Suhuang Zhike Capsules on basis of treatment in control group, 3 capsules each time, 3 times daily. Both groups were treated continuously for 6 weeks. The therapeutic effects of two groups were observed. The serum inflammatory factors (IL-17, IL-8, TNF-α, CRP], pulmonary function-related indicators (PEF, MEP, FEV1, FEV1/FVC), oxidative stress response indicators (MDA, SOD, GSH), and CAT score were compared between two groups. Results After treatment, the total effective rate of treatment group was 97.92%, significantly higher than that of control group (79.17) (P < 0.05). After treatment, the levels of IL-17, IL-8, TNF-α, and CRP in both groups were significantly lower than those before treatment in same group (P < 0.05). After treatment, the levels of IL-17, IL-8, TNF-α, and CRP in treatment group were all lower than those in control group (P< 0.05). After treatment, PEF, MEP, FEV1, and FEV1/FVC in both groups increased (P < 0.05). After treatment, the PEF, MEP, FEV1, and FEV1/FVC in treatment group were higher than those in control group (P < 0.05). After treatment, MDA decreased in both groups, but SOD and GSH increased (P < 0.05). After treatment, MDA in treatment group was lower than that in control group, but SOD and GSH were higher than those in control group (P < 0.05). After treatment, CAT score in both groups decreased significantly compared with that before treatment in same group (P < 0.05). After treatment, the CAT score of treatment group was lower than that of control group (P < 0.05). Conclusion Suhuang Zhike Capsule combined with budigafol can improve the clinical efficacy of elderly patients with COPD in remission, correct the inflammatory state, improve oxidative stress response, enhance lung function, which is also beneficial for improving life quality of patients.

R974

国家重点研发计划项目（2020YFC2005400）；北京市中医药科技项目（BJZYYB-2023-34）